Clinical Trials Logo

EBV clinical trials

View clinical trials related to EBV.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03699904 Terminated - COPD Clinical Trials

Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial

EViSCO
Start date: October 11, 2018
Phase: Phase 2
Study type: Interventional

COPD is a major public health problem and will shortly become the third most common cause of global mortality. There are currently no treatments that can meaningfully alter the progression of COPD or the time to death. Consequently novel therapeutic strategies for COPD are urgently required. This will be a randomised, double-blind, placebo-controlled, trial of Epstein-Barr virus suppression in COPD. Participants will be randomised to receive valaciclovir 1 gram three times daily for 8 weeks or matching placebo. The study will measure EBV suppression using quantitative PCR. Secondary outcomes will include Lung function quality of life and drug tolerability. The exploratory analysis will evaluate biomarkers of airway inflammation within the sputum and blood.

NCT ID: NCT02080416 Terminated - Gastric Cancer Clinical Trials

Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors

Start date: July 2014
Phase: Phase 0
Study type: Interventional

The goals of this study is to determine if nelfinavir can target Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) in patients with certain cancers.

NCT ID: NCT01948180 Terminated - EBV Clinical Trials

Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma

CITADEL
Start date: September 2014
Phase: Phase 2
Study type: Interventional

To investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma